Randomized, Double-Blind, Placebo-Controlled Ph2 BLU-285 in Indolent and Smoldering Systemic
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Blueprint Medicines Corporation
Start Date
May 5, 2021
End Date
May 14, 2026
Administered By
Duke Cancer Institute
Awarded By
Blueprint Medicines Corporation
Start Date
May 5, 2021
End Date
May 14, 2026